Men with benign prostatic hyperplasia (BPH) will soon have a therapeutic option that uses a unique drug delivery system. The FDA recently approved alfuzosin (UroXatral, Sanofi-Synthelabo) extended-release tablets for the treatment of the signs and symptoms of BPH. Alfuzosin is not indicated for the treatment of hypertension. The manufacturer expects alfuzosin to be available in pharmacies sometime in the second half of 2003.
Mental Health and CBD: What's the Latest Info
October 27th 2022Drug Topics® is joined by Dr. Alex Capano, Chief Science Officer at Ananda Professional to discuss what CBD is used for mental health, where research should go next, and how to ensure that patients are getting effective CBD products.
2 Clarke Drive
Cranbury, NJ 08512